Search

Your search keyword '"Nakas, Apostolos"' showing total 230 results

Search Constraints

Start Over You searched for: Author "Nakas, Apostolos" Remove constraint Author: "Nakas, Apostolos"
230 results on '"Nakas, Apostolos"'

Search Results

1. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma

3. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.

4. 61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma

6. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

7. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

9. Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

12. Data from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma

13. Table S3 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma

14. Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma

15. Body composition and lung cancer-associated cachexia in TRACERx

16. The evolution of non-small cell lung cancer metastases in TRACERx

17. The evolution of lung cancer and impact of subclonal selection in TRACERx

18. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

20. Extracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells

21. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

24. Abstract 6086: Clonal biallelic inactivation of NF2 is an evolutionary bottleneck that exposes a vulnerability to CDK7 inhibition in mesothelioma

25. Abstract 1613: Systematic screening for genomic vulnerabilities as drug targets for mesothelioma

28. MesobanK UK: an international mesothelioma bioresource

31. Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma

32. Increase in lung cancer emergency presentations during the COVID-19 pandemic

33. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

34. Lung cancer upstaging due to the COVID-19 pandemic

35. BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma

38. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

42. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

43. Abstract 2908: Mesothelioma phylogeny reveal MTAP as a solitary clonal deletion, exposing vulnerability to the PRMT5 perturbagen, quinacrine

45. Fc-Optimized Anti-CD25 depletes tumor-infiltrating regulatory T Cells and synergizes with PD-1 Blockade to eradicate established tumors

46. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

47. BTS guideline for the investigation and management of malignant pleural mesothelioma

48. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells

49. Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

50. Author response: Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells

Catalog

Books, media, physical & digital resources